TRYVIO/JERAYGO Drug Insight

“TRYVIO/JERAYGO Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about TRYVIO/JERAYGO for Treatment-resistant Hypertension in the 7MM. A detailed picture of the TRYVIO/JERAYGO for Treatment-resistant Hypertension in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the TRYVIO/JERAYGO for Treatment-resistant Hypertension. The report provides insight about TRYVIO/JERAYGO mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TRYVIO/JERAYGO market forecast, analysis for Treatment-resistant Hypertension in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Treatment-resistant Hypertension.

Drug Summary

TRYVIO is a once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. TRYVIO has a low potential for drug-drug interaction and a mechanism of action that is ideally suited for lowering blood pressure in adult patients whose hypertension is not adequately controlled by other drugs.

Aprocitentan is only available in the US under the tradename TRYVIO and is approved in the European Union and the UK under the tradename JERAYGO, with marketing authorization applications under review in Canada, and Switzerland. It is the first oral antihypertensive drug in a new class to be approved in nearly 40 years.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the TRYVIO/JERAYGO mechanism of action, description, dosage and administration, research and development activities in Treatment-resistant Hypertension.
•  Elaborated details on TRYVIO/JERAYGO regulatory milestones and other development activities have been provided in this report.
•  The endothelin receptor antagonist market report also highlights the TRYVIO/JERAYGO research and development activity in Treatment-resistant Hypertension details across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around TRYVIO/JERAYGO.
•  The report contains forecasted sales of TRYVIO/JERAYGO for Treatment-resistant Hypertension till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Treatment-resistant Hypertension.
•  The report also features the SWOT analysis with analyst views for TRYVIO/JERAYGO in Treatment-resistant Hypertension.

Methodology

The endothelin receptor antagonist market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TRYVIO/JERAYGO Analytical Perspective by DelveInsight

• In-depth TRYVIO/JERAYGO Market Assessment

This report provides a detailed market assessment of TRYVIO/JERAYGO in Treatment-resistant Hypertension in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

•  TRYVIO/JERAYGO Clinical Assessment

The report provides the clinical trials information of TRYVIO/JERAYGO for Treatment-resistant Hypertension covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Treatment-resistant Hypertension is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TRYVIO/JERAYGO dominance.
•  Other emerging products for Treatment-resistant Hypertension are expected to give tough market competition to TRYVIO/JERAYGO and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TRYVIO/JERAYGO in Treatment-resistant Hypertension.
•  Our in-depth analysis of the forecasted sales data of TRYVIO/JERAYGO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TRYVIO/JERAYGO in Treatment-resistant Hypertension.

Key Questions

•  What is the product type, route of administration and mechanism of action of TRYVIO/JERAYGO?
•  What is the clinical trial status of the study related to TRYVIO/JERAYGO in Treatment-resistant Hypertension and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TRYVIO/JERAYGO development?
•  What are the key designations that have been granted to TRYVIO/JERAYGO for Treatment-resistant Hypertension?
•  What is the forecasted market scenario of TRYVIO/JERAYGO for Treatment-resistant Hypertension?
•  What are the forecasted sales of TRYVIO/JERAYGO in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Treatment-resistant Hypertension and how are they giving competition to TRYVIO/JERAYGO for Treatment-resistant Hypertension?
•  Which are the late-stage emerging therapies under development for the treatment of Treatment-resistant Hypertension?